1. Hoyer J. Non-pharmacological and pharmacological treatment of arterial hypertension: current situation. Herz 2012; 37 (7): 728–34.
2. Widimsky J. The combination of an ACE inhibitor and a calcium channel blocker is an optimal combination for the treatment of hypertension. Vnitr Lek 2009; 55 (2): 123–30.
3. Farah R, Khamisy-Farah R, Shurtz-Swirski R. Calcium channel blocker effect on insulin resistance and inflammatory markers in essential hypertension patients. Int Angiol 2013; 32: 85–93.
4. Yeh JL, Hsu JH, Liang JC, et al. Lercanidipine and labedipinedilol-A attenuate lipopolysaccharideinterferon-gamma-induced inflammation in rat vascular smooth muscle cells. Atherosclerosis 2013; 226 (2): 364–72.
5. Sansanayudh N, Wongwiwatt S, Veerayuth S. Comparison of changes of body water measured by using bioelectrical impedance analysis between lercanidipine and amlodipine therapy in hypertensive outpatients. J Med Assoc Thai 2010; 93: 84–92.
6. Armario P, Waeber B. Therapeutic strategies to improve control of hypertension. J Hypertens 2013; 31 Suppl1: 9–12.
7. Krysiak R, Okopień B. Lymphocyte-suppressing action of angiotensin�converting enzyme inhibitors in coronary artery disease patients with normal BP. Pharmacol Rep 2011; 63: 1151–61.
8. Chen JL, Shang QH, Hu W, et al. Role of TGF/Smads pathway in carotid artery remodeling in renovascular hypertensive rats and prevention by enalapril and amlodipine. J Geriatr Cardiol 2012; 9: 185–91.
9. Hale TM, Robertson SJ, Burns KD, et al. Short-term ACE inhibition confers long-term protection against target organ damage. Hypertens Res 2012; 35: 604–10.
10. Velez Rueda JO, Palomeque J, Mattiazzi A, et al. Early apoptosis in different models of cardiac hypertrophy induced by high renin-angiotensinsystem activity involves CaMKII. J Appl Physiol 2012; 112: 2110–20.
11. Purclutepe O, Iskender G, Kiper HD, et al. Enalapril-induced apoptosis of acute promyelocytic leukaemia cells involves STAT5A. Anticancer Res 2012; 32: 2885–93.
12. Bowling CB, Sanders PW, Allman RM, et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease. Int J Cardiol 2012; Jan 16.
13. Funck-Brentano C, van Veldhuisen DJ, van de Ven LL, et al. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. Eur J Heart Fail 2011; 13: 765–72.
14. Shetty PK, Suthar NA, Menon J, et al. Transdermal delivery of lercanidipine hydrochloride. Curr Drug Deliv 2013; Jan 3.
15. Borghi C, Santi F. Fixed combination of lercanidipine and enalapril in the management of hypertension: focus on patient preference and adherence. Pt Prefer Adh 2012; 6: 449–55.
16. Bangalore S, Kamala G, Parker S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120 (8): 713–9.
17. Messerli FH. Review: fixed-dose drug combinations improve medication compliance compared with free-drug regimens. Evid Based Med 2008; 13: 18–22.
18. Gupta AK, Arshad S, Poulter NR. Compliance, Safety and Effectiveness of fixed-dose combinations of antihypertensive agents. Hypertension 2010; 55: 399–407.
19. Cicero AF, Gerocarni B, Rosticci M, et al. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. Clin Exp Hypertens 2012; 34 (2): 113–7.
20. Egan CG, Pontremoli R. Role of th fixed-dose combination lercanidipine-enalapril in renal protection. J Nephrol 2011; 24 (4): 426–37.
